Search Within

Sergio Andres Giralt

Formats
  1. Meeting Abstract (632)
  2. Journal Article (373)
  3. Research Letter (17)
  4. Review (15)
  5. Guidelines (5)
  6. Editorial (4)
  7. Book Section (3)
  8. Correspondence (3)
Groups
  1. Bone Marrow Transplant (1052)
  2. Center for Hematologic Malignancies (1052)
  3. Department of Medicine (1052)
  4. Hematologic Malignancies, Division of (1052)
  5. Survivorship Research (686)
  6. CTCR Scholars (541)

More Groups

People
  1. Miguel-Angel Perales (422)
  2. Sean Devlin (372)
  3. Gunjan Shah (298)
  4. Michael Scordo (267)
  5. Heather Landau (253)
  6. Ann Jakubowski (240)

More People

Years
  1. 2025 (11)
  2. 2024 (55)
  3. 2023 (104)
  4. 2022 (77)
  5. 2021 (66)
  6. 2020 (91)

More Years

Publications
  1. Blood (304)
  2. Biology of Blood and Marrow Transplantation (275)
  3. Bone Marrow Transplantation (80)
  4. Clinical Lymphoma, Myeloma and Leukemia (60)
  5. Journal of Clinical Oncology (40)
  6. Transplantation and Cellular Therapy (36)

More Publications

Publishers
  1. Elsevier Inc. (384)
  2. American Society of Hematology (337)
  3. Nature Publishing Group (108)
  4. American Society of Clinical Oncology (42)
  5. Taylor & Francis Group (35)
  6. Ferrata Storti Foundation (13)

More Publishers

Results (1052)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evolving M-spike and risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Nemirovsky, D.; Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Adding Plinabulin to pegfilgrastim to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant for multiple myeloma
    Meeting Abstract

    Shah, G.; Hanley, D.; Datta, A.; Kamrowski, A.; Chung, D.; Gupta, G.; Hassoun, H.; Hoover, E.; Hultcrantz, M.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Nath, K.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Vitamin D deficiency and clinical outcomes with chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KarMMa-3 high-risk subgroup analysis
    Meeting Abstract

    Patel, K.; Rodríguez-Otero, P.; Manier, S.; Baz, R.; Raab, M.; Cavo, M.; Callander, N.; Costa, L.; Moreau, P.; Solomon, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evaluating dynamic changes in the serum free light chain ratio and its effect on risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Nemirovsky, D.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Ide-cel versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KarMMa-3 analysis in the modified intention to-treat (mITT) population
    Meeting Abstract

    Manier, S.; Ailawadhi, S.; Rodríguez-Otero, P.; Arnulf, B.; Patel, K.; Solomon, S.; Baz, R.; Jagannath, S.; Raje, N.; Scheid, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Prognostic impact of corticosteroid and tocilizumab use on the efficacy of chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Flynn, J.; Nath, K.; Nishimura, N.; Devlin, S.; Farzana, T.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Patterns of cytokine release syndrome with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
    Meeting Abstract

    Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Bispecific T-cell engager response is driven by pre-treatment CD8+ effector memory cells and inhibited by TIGIT+ Tregs in relapsed/refractory multiple myeloma
    Meeting Abstract

    Firestone, R.; McAvoy, D.; Shekarkhand, T.; Serrano, E.; Hamadeh, I.; Wang, A.; Zhu, M.; Patel, D.; Tan, C. R.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save